alexa Engineering A New Class Of Antibiotic Against An RNA Target | 72841
ISSN: 2329-8936

Transcriptomics: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

2nd International Conference on Molecular Biology, Nucleic Acids & Molecular Medicine
August 31-September 01, 2017 Philadelphia, USA

Paul F Agris
The RNA Institute, USA
Keynote: Transcriptomics
DOI: 10.4172/2329-8936-C1-011
Abstract
Constantly evolving drug-resistant and multidrug-resistant (MDR) Gram-positive pathogens such as Staphylococcus aureus (methicillin-resistant, MRSA), Streptococcus pneumoniae and Clostridium difficile represent an ever-increasing source of morbidity and mortality in the USA. A new class of topically applied antibiotics against MRSA and other dangerous multi-drug resistant pathogenic infections such as staphylococci and streptococci has been developed. Some bacteria are even developing resistance to vancomycin, an antibiotic drug of last resort. To address these demands, we have selected, screened and characterized a novel putative antibiotic that has little-to-no toxicity, and to which bacteria are slow to develop resistance. This new class of antibiotic targets a ribonucleic acid (RNA) in the cell, rather than a protein. The RNA target is unique to Gram-positive bacteria and is not found in humans, and it is important to basic functions required for the bacteria to live. Our small molecule antibiotic drug turns OFF the RNA function, simultaneously halting expression of as many as 24 genes critical in bacteria, killing the pathogens. Preliminary studies indicate that the new antibiotic is effective against bacteria that had been isolated from humans, is not toxic to human cells in lab cultures at doses effective against bacteria, and is not toxic in preliminary topical animal studies.
Biography

Paul F. Agris created and is the founding Director of The RNA Institute, SUNY at Albany. He is known as a Structural Biochemist and innovator in RNA biology, RNA modification science and applications, and nucleic acid design with modified nucleosides. Agris was a Professor and Head of North Carolina State University’s Biochemistry Department, and founded and led the RNA Society of North Carolina for more than a decade. Previously, he was an Assistant, Associate and full Professor in the Division of Biological Sciences and Department of Medicine at the University of Missouri-Columbia. Agris researches into RNA-based therapeutics against infective disease, drug-resistant HIV and MRSA, have been supported continuously by federal agencies since 1974. He is the author of some 170 peer reviewed articles, a number of reviews, chapters and editor of three volumes. Agris founded the RNA-based drug discovery company SIRGA Advanced Biopharma, Inc., Research Triangle Park, NC.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version